Fortis Healthcare Limited announced the outcome of its Board meeting held on February 13, 2026. Key approvals include the Un-Audited Standalone and Consolidated Financial Results for the quarter and period ended December 31, 2025. The Board also approved the formulation of the Fortis Healthcare Limited Employee Stock Option Scheme 2026 (ESOP 2026) and a revision to the Related Party Transaction Policy.
Quarterly Financial Results Approved
The Board of Directors, following a meeting on Friday, February 13, 2026, approved the Un-Audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The results, along with the Limited Review Report from the Statutory Auditors, have been submitted.
Standalone Performance Highlights (Quarter Ended Dec 31, 2025)
- Revenue from operations stood at ₹44,293 lacs.
- Net profit/(loss) for the period from continuing operations was ₹2,840 lacs.
- Net profit/(loss) for the period (total) was ₹2,840 lacs.
- Basic Earnings Per Share (EPS) from continuing operations was ₹0.38.
Consolidated Performance Highlights (Quarter Ended Dec 31, 2025)
- Total Income reached ₹227,330 lacs.
- Total Expenses were ₹196,524 lacs.
- Net profit/(loss) for the period from continuing operations was ₹19,740 lacs.
- Basic EPS from continuing operations was ₹2.57.
- The Group reported an exceptional loss of (₹4,591 lacs) for the quarter.
New Employee Stock Option Scheme (ESOP 2026)
The Board, based on the recommendation of the Nomination and Remuneration Committee, approved the formulation and implementation of the Fortis Healthcare Limited Employee Stock Option Scheme 2026 (“ESOP 2026”). This scheme is subject to shareholder approval and other regulatory clearances.
Key details of the proposed scheme include:
- A pool of 1,50,99,163 Options are proposed to be granted.
- Each Option will entitle the holder to one fully paid-up equity share of face value of ₹10/-.
- The exercise price will equal the market price on the relevant date, but not less than the face value.
- The exercise period for vested Options will be a maximum of 4 years from the date of vesting.
Policy Revision and Regulatory Notes
The Board also approved a Revision in Related Party Transaction Policy, with the updated policy attached. The associated disclosures detail extensive ongoing regulatory matters, including investigations by the Serious Fraud Investigation Office (SFIO) concerning historical transactions prior to March 31, 2018, and legal proceedings related to property and brand ownership disputes.
Regarding financial covenants for listed non-convertible debt securities, the auditors noted that the covenant testing (Net External Debt to EBITDA ratio not exceeding 4x) is required annually on audited consolidated accounts, and therefore, was not required to be tested for the quarter ended December 31, 2025.
Source: BSE
